Rebecca Taub Sells 648 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub sold 648 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $217,235.52. Following the sale, the chief marketing officer now directly owns 456,662 shares in the company, valued at $153,091,368.88. The trade was a 0.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Rebecca Taub also recently made the following trade(s):

• On Friday, January 17th, Rebecca Taub sold 1,689 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $273.41, for a total value of $461,789.49.

Madrigal Pharmaceuticals Trading Up 5.3 %

Shares of MDGL opened at $327.35 on Wednesday. The stock has a fifty day moving average price of $314.78 and a two-hundred day moving average price of $274.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. Madrigal Pharmaceuticals, Inc. has a 52-week low of $168.25 and a 52-week high of $368.29. The company has a market cap of $7.14 billion, a price-to-earnings ratio of -13.05 and a beta of -0.36.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.94) by $2.02. The business had revenue of $62.18 million during the quarter, compared to the consensus estimate of $34.60 million. During the same quarter in the previous year, the firm posted ($5.34) EPS. Analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Braidwell LP bought a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $39,010,000. Eagle Asset Management Inc. bought a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $6,875,000. Intech Investment Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $1,280,000. Vestal Point Capital LP acquired a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $6,367,000. Finally, Blueshift Asset Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $393,000. Institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MDGL. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a report on Saturday, October 12th. Oppenheimer decreased their price objective on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. JMP Securities restated a “market outperform” rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. Finally, UBS Group raised their target price on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, Madrigal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $351.67.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.